BioCryst Pharmaceuticals

Yahoo Finance • 22 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock opti... Full story

Yahoo Finance • last month

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September... Full story

Yahoo Finance • last month

BioCryst Announces Departure of Dr. Helen Thackray

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and t... Full story

Yahoo Finance • 2 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ...

Total Revenue: $163.4 million for Q2 2025. ORLADEYO Revenue: $156.8 million, with $140.3 million generated in the US. ORLADEYO Revenue Growth: 45% increase year-over-year for Q2. Non-GAAP Operating Expenses: $106.4 million for Q2 2025, up... Full story

Yahoo Finance • 2 months ago

BioCryst Pharma soars 6.4% as Q2 results crush expectations

Investing.com -- BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX) shares surged 6.4% after the company reported second-quarter earnings that significantly exceeded analyst expectations, driven by record-breaking sales of its hereditary angio... Full story

Yahoo Finance • 2 months ago

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX [https://www.chartmill.com/stock/quote/BCRX]) SURPASSES Q2 2025 ESTIMATES WITH STRONG REVENUE AND PROFIT GROWTH BioCryst Pharmaceuticals Inc (NASDAQ:BCRX [https://www.chartmill.com/stock/quote/BCR... Full story

Yahoo Finance • 2 months ago

BioCryst: Q2 Earnings Snapshot

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported second-quarter net income of $5.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Durham, North C... Full story

Yahoo Finance • 2 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Pharmaceuticals, Inc. —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y)— —Compa... Full story

Yahoo Finance • 2 months ago

Stocks Set to Open Higher as Investors Bet on Fed Rate Cuts

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Transocean Ltd. (RIG [https://seekingalpha.com/symbol/RIG]) * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * BioNTech SE (BNTX [https://seekingal... Full story

Yahoo Finance • 2 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his inte... Full story

Yahoo Finance • 2 months ago

RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target... Full story

Yahoo Finance • 3 months ago

BioCryst appoints Babar Ghias as CFO

* BioCryst Pharmaceuticals (NASDAQ:BCRX [https://seekingalpha.com/symbol/BCRX]) on Monday announced the appointment of Babar Ghias as chief financial officer and head of corporate development. * Ghias joins BioCryst from AvenCell Thera... Full story

Yahoo Finance • 3 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias j... Full story

Yahoo Finance • 3 months ago

BioCryst to sell European Orladeyo business for up to $264M

[Large Sale sign in white and red in a retail shop window] Adam Webb/iStock via Getty Images BioCryst Pharmaceuticals (NASDAQ:BCRX [https://seekingalpha.com/symbol/BCRX]) on Friday announced an agreement to sell European business related... Full story

Yahoo Finance • 3 months ago

BioCryst to sell European ORLADEYO business to Neopharmed for $264M

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), which has seen its stock surge over 58% in the past year according to InvestingPro data, has entered into an agreement to sell its European ORLADEYO business to N... Full story

Yahoo Finance • 3 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will e... Full story

Yahoo Finance • 4 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been a... Full story

Yahoo Finance • 4 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioed... Full story

Yahoo Finance • 4 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms amon... Full story